Cutaneous leishmaniasis
Drug research and approvals for cutaneous leishmaniasis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 11 studies of cutaneous leishmaniasis are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 1 approved and 5 open orphan designations naming it.
- Recruiting worldwide: 11
- Trials authorized in Canada: 0
- FDA orphan approvals: 1
- EU medicines: 0
- High-Frequency Ultrasound Monitoring of Cutaneous Leishmaniasis During TreatmentNCT07934446 · Not reported · University of Brasilia · starts Jan 8, 2025
- Ex Vivo Immunogenicity Screening of Vaccine Candidate Antigen Combinations in Ethiopian Patients With LeishmaniasisNCT07783243 · Not reported · Institute of Tropical Medicine, Belgium · starts May 26, 2026
- LEISH-PED: Study on Leishmaniasis in ChildrenNCT07504757 · Not reported · Meyer Children's Hospital IRCCS · starts Jan 30, 2025
- Arnica Tincture Fot the Treatment of Cutaneous Leishmaniasis II.NCT06822478 · Phase 3 · Universidad de Antioquia · starts Mar 11, 2026
- Intralesional Injection of Metronidazole for the Management of Cutaneous LeishmaniasisNCT06798415 · Phase 2 · Hayder Adnan Fawzi · starts Feb 10, 2025
- Ciprofloxacin Intralesional Injection for the Treatment of Cutaneous Leishmaniasis Compared to Sodium StibogluconateNCT06798402 · Phase 2 · Al-Mustafa University College · starts Feb 7, 2025
- Intralesional Injection of Levofloxacin for the Management of Cutaneous LeishmaniasisNCT06797544 · Phase 2 · Hayder Adnan Fawzi · starts Feb 9, 2025
- Feasibility of Integrating Thermotherapy for Treatment of Cutaneous Leishmaniasis in Primary Health Care SetupNCT06746350 · Not applicable · Armauer Hansen Research Institute, Ethiopia · starts Apr 24, 2025
- Treatment of Bolivian L Braziliensis Mucosal Leishmaniasis With Inhaled Pentamidine Plus Oral MiltefosineNCT06550609 · Phase 2 · Fundacion Nacional de Dermatologia · starts Feb 4, 2025
Approved 1
Phase 3 5
- Meglumine antimonate
- ParomomycinBacterial 70S ribosome inhibitor
- ImiquimodToll-like receptor 7 agonist
- Nitric oxideSoluble guanylate cyclase activator
- FluconazoleCytochrome P450 51 inhibitor
Phase 2 7
- PentoxifyllineAdenosine A2 receptor antagonist
- Stibogluconic acid
- Antimony
- GentamicinBacterial 70S ribosome inhibitor
- TofacitinibJanus Kinase (JAK) inhibitor
- SargramostimGranulocyte-macrophage colony-stimulating factor receptor agonist
- Antimony cation (5+)
Phase 1 or earlier 2
- Amphotericin bErgosterol sequestering agent
- Aluminum hydroxideAntacid
How its trials ended
103 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 31 whose ending is known, 39% met their primary endpoint, 19% missed it and 42% stopped early.
- Completed, result not reported5150%
- Met its primary endpoint1212%
- Ongoing1212%
- Status unknown99%
- Missed its primary endpoint66%
- Stopped: lack of efficacy55%
- Stopped: other or unclear55%
- Stopped: enrollment or feasibility22%
- Stopped: sponsor or business decision11%
| Mar 19, 2014 | ImpavidoTreatment of visceral leishmaniasis due to Leishmania donovani; cutaneous leishmaniasis due to Leishmania braziliensis, Leishmania… | Knight Therapeutics (USA) | Approved |
| Jan 23, 2024 | Imiquimod-Ferulic AcidTreatment of Cutaneous Leishmaniasis | Celista Pharmaceuticals LLC | Designated |
| Jul 19, 2021 | (2S)-2-[(2S)-4-cyclohexyl-2-{[(2S)-1-(4-fluorobenzoyl)pyrrol…Treatment of cutaneous leishmaniasis (Old World and New World) | Bacoba AG | Designated |
| Feb 11, 2015 | ParomomycinTreatment of cutaneous leishmaniasis (Old World and New World) | Appili Therapeutics Inc. | Designated |
| Jan 18, 2008 | Paromomycin sulfate/gentamicin sulfateTreatment of all uncomplicated cutaneous leishmaniasis (both New World and Old World) | Appili Therapeutics Inc. | Designated |
| Jun 16, 2006 | Sodium stibogluconateTreatment of cutaneous leishmaniasis | VioQuest Pharmaceuticals, Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA